NETRAMARK HLDGS INC (AINMF)
AINMF moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How AINMF actually reacts to news — the realized, point-in-time move the market made, measured across 58 labeled events over the last three years with zero look-ahead.
AINMF’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 18% | 28 |
| 30-min | 0.00% | 14% | 28 |
| 60-min | 0.00% | 21% | 28 |
| to close | 0.00% | 31% | 29 |
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when AINMF moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AINMF's baseline. Nothing else.
Recent AINMF events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Netramark Announces Uplisting to Toronto Stock Exchange | Press release | GlobeNewswire | — | — | |
| NetraMark Strengthens Board Of Directors | Press release | GlobeNewswire | +0.00% | +0.00% | |
| NetraMark Closes First Tranche of Private Placement | Press release | GlobeNewswire | +0.48% | +0.48% | |
| NetraMark Engages LodeRock Advisors for Strategic Investor Relations and Capital Markets Communications Services | Press release | GlobeNewswire | +0.00% | -2.77% | |
| NetraMark Announces Private Placement Financing | Press release | GlobeNewswire | — | — | |
| NetraMark Delivers Transformational Quarter Of Execution | Press release | GlobeNewswire | — | — | |
| NetraMark and CAMH Announce Research Award to Advance AI-Driven Discovery in Schizophrenia and Depression | Press release | GlobeNewswire | +0.00% | +0.00% | |
| NetraMark Achieves Major FDA Milestone | Press release | GlobeNewswire | +0.00% | -0.13% | |
| NetraMark Continues Expansion Into Phase 3 Programs With Contract From Global Biopharmaceutical Company | Press release | GlobeNewswire | — | — | |
| NetraAI Study Accepted for Publication in npj Digital Medicine, Part of the Nature Portfolio | Press release | GlobeNewswire | +0.00% | -0.83% | |
| NetraMark Signs Four New Contracts With a Leading Global Pharmaceutical Company To Enhance Clinical Trial Insights | Press release | GlobeNewswire | — | — | |
| Netramark Signs Contract with a Leading Global Biopharmaceutical Company to Enhance Clinical Trial Insights | Press release | GlobeNewswire | — | — | |
| NetraMark Presents AI-Driven Advances in Precision Psychiatry to Enhance Clinical Trial Designs at Joint Autumn Conference | Press release | GlobeNewswire | — | — | |
| NetraMark Initiates AI-Driven Collaboration in Glioblastoma Research | Press release | GlobeNewswire | — | — | |
| NetraMark Appoints Jan Sedway as Senior Vice President of Clinical Science to Accelerate Growth and Market Leadership | Press release | GlobeNewswire | — | — | |
| Asklepion Pharmaceuticals Signs Contract to Utilize NetraMark Technology in Phase III Pediatric Cardiac Study | Press release | GlobeNewswire | +0.00% | +0.00% | |
| NetraMark to Attend Canaccord Genuity’s 45th Annual Growth Conference | Press release | GlobeNewswire | +0.00% | +0.00% | |
| NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity | Press release | GlobeNewswire | +0.00% | +0.00% | |
| NetraMark Signs Contract with AlgoTx to Enhance Clinical Trial Design for ATX01 | Press release | GlobeNewswire | +0.00% | +0.00% | |
| NetraMark's AI Significantly Outperforms ChatGPT, DeepSeek and Traditional Machine Learning in Clinical Trial Subpopulation Discovery, Offers New Path for Trial Success | Press release | GlobeNewswire | — | — | |
| NetraMark Founder Coauthors New Publication on AI/ML Use in Clinical Trials, Alongside Authors From Leading Global Regulatory Organizations | Press release | GlobeNewswire | — | — | |
| NetraMark Completes 2025 Annual General Meeting | Press release | GlobeNewswire | +0.00% | +0.00% | |
| NETRAMARK TO HOST SHAREHOLDER CONFERENCE CALL TO DISCUSS BUSINESS MOMENTUM | Press release | Canada Newswire | +0.53% | +0.43% | |
| NETRAMARK AND WORLDWIDE CLINICAL TRIALS ANNOUNCE AGREEMENT TO TRANSFORM CLINICAL TRIAL DESIGN WITH AI-POWERED PRECISION | Press release | PR Newswire | +0.00% | +6.91% | |
| NETRAMARK STRENGTHENS FINANCIAL POSITION WITH ADDITIONAL $1,853,054 RAISED FROM WARRANT EXERCISE | Press release | Canada Newswire | +0.00% | -9.54% | |
| NETRAMARK UNVEILS AI DRIVEN INSIGHTS FOR MAJOR DEPRESSIVE DISORDER AND SCHIZOPHRENIA AT ISCTM CONFERENCE | Press release | Canada Newswire | +0.00% | +2.01% | |
| NETRAMARK AND THE ONTARIO BRAIN INSTITUTE PARTNER TO ADVANCE AI-POWERED NEUROANALYTICS FOR MAJOR DEPRESSION RESEARCH | Press release | Canada Newswire | -11.77% | -15.97% | |
| NETRAMARK TO PRESENT NOVEL AI-BASED CLINICAL TRIAL TREATMENT SEPARATION TOOLS AT ISCTM ANNUAL MEETING | Press release | Canada Newswire | -6.39% | -4.26% | |
| NETRAMARK TO PRESENT NOVEL AI-BASED CLINICAL TRIAL TREATMENT SEPARATION TOOLS AT ISCTM ANNUAL MEETING | Press release | Canada Newswire | +0.00% | +5.74% | |
| NETRAMARK LAUNCHES NETRAAI 2.0: ADVANCING CLINICAL TRIAL ANALYSIS WITH AI-POWERED INSIGHTS | Press release | Canada Newswire | +0.00% | +1.41% | |
| NETRAMARK PROVIDES BUSINESS UPDATE | Press release | Canada Newswire | — | — | |
| NETRAMARK STRENGTHENS FINANCIAL POSITION WITH $1,161,000 RAISED FROM WARRANT AND STOCK OPTION EXERCISE | Press release | Canada Newswire | +0.00% | +0.00% | |
| NETRAMARK EXPANDS TEAM WITH THE ADDITION OF INDUSTRY VETERAN | Press release | Canada Newswire | +2.60% | -5.34% | |
| NETRAMARK SIGNS A PILOT COLLABORATION AGREEMENT WITH A TOP 5 PHARMACEUTICAL COMPANY | Press release | Canada Newswire | +1.46% | -3.03% | |
| NETRAMARK EXPANDS PRODUCT OFFERINGS TO ADDRESS CORE CLINICAL TRIAL CHALLENGES AND IMPROVE MARKET ACCESS SUCCESS | Press release | Canada Newswire | — | — | |
| NETRAMARK PROVIDES Q3 BUSINESS UPDATE AND HIGHLIGHTS PROGRESS | Press release | Canada Newswire | — | — | |
| NETRAMARK ANNOUNCES COLLABORATION AGREEMENT WITH NIMH TO ANALYZE CLINICAL TRIAL DATA ON THE USE OF KETAMINE IN PSYCHIATRIC DISORDERS | Press release | Canada Newswire | +0.00% | +0.00% | |
| NETRAMARK TO INTRODUCE THE TREATMENT ATTITUDE PROFILE (TAP™) SCALE FOR PLACEBO RESPONSE PERSONA DISCOVERY USING ITS NETRA AI TECHNOLOGY AT THE 2024 ASCP ANNUAL MEETING | Press release | Canada Newswire | — | — | |
| NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES NOVEL LUNG AND COLON CANCER BIOMARKERS AND PATIENT SUBPOPULATIONS | Press release | Canada Newswire | — | — | |
| NETRAMARK ANNOUNCES SHAREHOLDER MEETING RESULTS | Press release | Canada Newswire | — | — | |
| PHARMACEUTICAL INDUSTRY VETERAN JOINS NETRAMARK ADVISORY BOARD | Press release | Canada Newswire | — | — | |
| NETRAMARK PROVIDES BUSINESS UPDATE AND HIGHLIGHTS PROGRESS | Press release | Canada Newswire | — | — | |
| NETRAMARK SIGNS CONTRACT WITH PHARMACEUTICAL COMPANY TO DELIVER CLINICAL TRIAL INSIGHTS REGARDING EFFICACY AND PLACEBO RESPONSE | Press release | Canada Newswire | — | — | |
| NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES PARKINSON'S DISEASE SUBTYPES LINKED BY MITOCHONDRIAL, MICROBIOME AND IMMUNE SIGNALING | Press release | Canada Newswire | — | — | |
| NETRAMARK TO PRESENT NEW DATA HIGHLIGHTING THE UTILITY OF IT'S AI-BASED CLINICAL SOLUTION IN IDENTIFYING PARKINSON'S DISEASE ASSOCIATED BIOMARKERS AT AD/PD™ 2024 | Press release | Canada Newswire | — | — | |
| NETRAMARK SIGNS FOURTH CONTRACT WITH LARGE BIOPHARMACEUTICAL COMPANY TO ENHANCE CLINICAL TRIAL INSIGHTS | Press release | Canada Newswire | — | — | |
| NETRAMARK'S AI-BASED TECHNOLOGY IDENTIFIES SIGNIFICANT DRIVERS OF EFFICACY AND PLACEBO RESPONSES AND HAS POTENTIAL TO IMPROVE SUCCESS RATES FOR CLINICAL TRIALS OF PSYCHIATRIC MEDICATIONS | Press release | Canada Newswire | — | — | |
| NETRAMARK TO PRESENT NEW DATA DEMONSTRATING THE POWER OF ITS AI BASED TECHNOLOGY TO DE-RISK NEUROLOGY CLINICAL TRIALS AT ISCTM ANNUAL MEETING | Press release | Canada Newswire | — | — | |
| NETRAMARK ANNOUNCES LAUNCH OF THE NETRA AI LAB | Press release | Canada Newswire | — | — | |
| NETRAMARK SIGNS THIRD CONTRACT WITH LARGE BIOPHARMACEUTICAL COMPANY TO ENHANCE CLINICAL TRIAL INSIGHTS | Press release | Canada Newswire | +0.00% | +1.71% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AINMF section they belong to.
Where else AINMF is measured.
AINMF earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is NETRAMARK HLDGS INC's median reaction calculated?
Every labeled AINMF news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 58 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 14% of AINMF's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AINMF's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.